Physician profile
John N Troccoli
NPI 1861492977
$7,741.65
in general payments reported to CMS, 2019-2025
33 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $516 · 2021: $713 · 2022: $1,020 · 2023: $1,560 · 2024: $1,462 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,699.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,567.47 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $863.44 | 2019-2025 | |
| Pfizer INC. | $779.17 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $765.39 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $756.07 | 2019-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $673.69 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $327.38 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $324.72 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $316.95 | 2019-2025 | |
| Incyte Corporation | $209.30 | 2024-2025 | Opzelura |
| Dermavant Sciences, INC. | $165.55 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $152.46 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $115.32 | 2019-2023 | Dupixent |
| Cipher Pharmaceuticals US LLC | $82.46 | 2025 | Spinosad, Natroba |
| Verrica Pharmaceuticals INC. | $79.11 | 2023-2025 | Ycanth |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $76.92 | 2019-2021 | |
| Sebela Pharmaceuticals INC. | $63.95 | 2022-2023 | Pramosone, Naftin |
| Botanix Sb INC | $56.67 | 2025 | Sofdra |
| Solventum Corporation | $47.26 | 2025 | V.A.C. Veraflo, Prevena, V.A.C. Veraflo Cleanse Choice |
| Sanofi-Aventis U.S. LLC | $42.79 | 2020 | |
| Leo Pharma INC. | $40.68 | 2023-2024 | Adbry |
| Organon LLC | $37.02 | 2025 | Vtama, Nexplanon |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.37 | 2019 | |
| Kyowa Kirin, INC. | $23.75 | 2021 | |
| Biofrontera INC. | $22.20 | 2019 | |
| Merz North America, INC. | $17.98 | 2021 | |
| Almirall LLC | $17.89 | 2019 | |
| Mission Pharmacal Company | $17.44 | 2021 | |
| Fidia Pharma USA INC. | $15.93 | 2024 | |
| Genzyme Corporation | $15.73 | 2021 | |
| Galderma Laboratories, L.P. | $14.72 | 2020 | |
| Strata Skin Sciences, INC. | $14.25 | 2025 | Xtrac |
| Merck Sharp & Dohme LLC | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Troccoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.